<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>PK Profile Analysis & Patent Differentiation - Extended-Release Minoxidil</title>
    <style>
        body {
            font-family: 'Arial', sans-serif;
            line-height: 1.6;
            max-width: 950px;
            margin: 0 auto;
            padding: 40px 20px;
            color: #333;
        }
        h1 {
            color: #1a73e8;
            border-bottom: 3px solid #1a73e8;
            padding-bottom: 10px;
        }
        h2 {
            color: #185abc;
            margin-top: 40px;
            border-bottom: 1px solid #ddd;
            padding-bottom: 5px;
        }
        h3 {
            color: #1967d2;
            margin-top: 25px;
        }
        table {
            border-collapse: collapse;
            width: 100%;
            margin: 15px 0;
        }
        th, td {
            border: 1px solid #ddd;
            padding: 10px 12px;
            text-align: left;
        }
        th {
            background-color: #f8f9fa;
            font-weight: bold;
            color: #185abc;
        }
        tr:nth-child(even) {
            background-color: #f8f9fa;
        }
        tr:hover {
            background-color: #e8f0fe;
        }
        .highlight {
            background-color: #fff3cd;
            padding: 15px;
            border-left: 4px solid #ffc107;
            margin: 20px 0;
        }
        .info-box {
            background-color: #e8f0fe;
            padding: 15px;
            border-left: 4px solid #1a73e8;
            margin: 20px 0;
        }
        .warning-box {
            background-color: #fce8e6;
            padding: 15px;
            border-left: 4px solid #d93025;
            margin: 20px 0;
        }
        .success-box {
            background-color: #e6f4ea;
            padding: 15px;
            border-left: 4px solid #34a853;
            margin: 20px 0;
        }
        .confidence-high {
            color: #137333;
            font-weight: bold;
        }
        .confidence-medium {
            color: #b45309;
            font-weight: bold;
        }
        .confidence-low {
            color: #c5221f;
            font-weight: bold;
        }
        hr {
            border: none;
            border-top: 1px solid #ddd;
            margin: 30px 0;
        }
        .badge {
            display: inline-block;
            padding: 4px 10px;
            border-radius: 12px;
            font-size: 12px;
            font-weight: bold;
            margin-right: 5px;
        }
        .badge-primary {
            background-color: #1a73e8;
            color: white;
        }
        .badge-success {
            background-color: #34a853;
            color: white;
        }
        .badge-warning {
            background-color: #fbbc04;
            color: #333;
        }
        ul, ol {
            margin: 10px 0;
            padding-left: 25px;
        }
        li {
            margin: 5px 0;
        }
    </style>
</head>
<body>

<h1>Pharmacokinetic Profile Analysis & Patent Differentiation</h1>
<p><strong>Alternative Extended-Release Minoxidil Formulations vs. Veradermics VDPHL01</strong></p>
<p><em>Prepared: February 5, 2026</em></p>

<hr>

<h2>Veradermics' Target PK Profile</h2>
<p>From patent <a href="https://patents.google.com/patent/US12268688B2/en">US12268688B2</a>:</p>

<table>
    <tr>
        <th>Parameter</th>
        <th>Veradermics Target</th>
        <th>Notes</th>
    </tr>
    <tr>
        <td><strong>Cmax</strong></td>
        <td>0.25 - 20 ng/mL</td>
        <td>Peak serum concentration</td>
    </tr>
    <tr>
        <td><strong>Tmax</strong></td>
        <td>0.5 - 6 hours (or delayed 6.5-18 hours)</td>
        <td>Time to peak concentration</td>
    </tr>
    <tr>
        <td><strong>Steady-state</strong></td>
        <td>1 - 20 ng/mL maintained â‰¥12 hours</td>
        <td>Therapeutic window</td>
    </tr>
    <tr>
        <td><strong>Release</strong></td>
        <td>50-98% within 12 hours</td>
        <td>In vitro dissolution</td>
    </tr>
    <tr>
        <td><strong>Cardiac threshold</strong></td>
        <td>Stay below ~20-25 ng/mL</td>
        <td>Safety ceiling</td>
    </tr>
    <tr>
        <td><strong>Dosing</strong></td>
        <td>8.5 mg BID (17 mg/day total)</td>
        <td>Per Phase 2/3 protocol</td>
    </tr>
</table>

<hr>

<h2>Our Formulations: Expected PK Profiles & Confidence Assessment</h2>

<table>
    <tr>
        <th>Formulation</th>
        <th>Expected PK Profile</th>
        <th>PK Confidence</th>
        <th>Patent Confidence</th>
        <th>Overall Risk</th>
    </tr>
    <tr>
        <td><strong>1. EOP</strong><br>(Elementary Osmotic Pump)</td>
        <td>Zero-order, very flat<br>Cmax ~8-12 ng/mL<br>Tmax 4-8h</td>
        <td class="confidence-high">Medium-High (75%)</td>
        <td class="confidence-high">High (90%)</td>
        <td>Low</td>
    </tr>
    <tr>
        <td><strong>2. CPOP</strong><br>(Controlled Porosity Osmotic)</td>
        <td>Near zero-order<br>Cmax ~10-15 ng/mL<br>Tmax 3-6h</td>
        <td class="confidence-medium">Medium (65%)</td>
        <td class="confidence-high">High (90%)</td>
        <td>Low-Medium</td>
    </tr>
    <tr style="background-color: #e6f4ea;">
        <td><strong>3. MUPS</strong> <span class="badge badge-success">RECOMMENDED</span><br>(Multi-Particulate System)</td>
        <td>First-order diffusion<br>Cmax ~12-18 ng/mL<br>Tmax 2-5h</td>
        <td class="confidence-high">High (85%)</td>
        <td class="confidence-high">Very High (95%)</td>
        <td><strong>Lowest</strong></td>
    </tr>
    <tr>
        <td><strong>4. Lipid Matrix</strong> <span class="badge badge-warning">2ND CHOICE</span></td>
        <td>Erosion-controlled<br>Cmax ~10-18 ng/mL<br>Tmax 3-6h</td>
        <td class="confidence-medium">Medium (60%)</td>
        <td class="confidence-high">Very High (95%)</td>
        <td>Low-Medium</td>
    </tr>
    <tr>
        <td><strong>5. Push-Pull</strong><br>(Bi-Layer Osmotic)</td>
        <td>Zero-order pump<br>Cmax ~8-12 ng/mL<br>Tmax 4-8h</td>
        <td class="confidence-medium">Medium (70%)</td>
        <td class="confidence-high">High (90%)</td>
        <td>Low</td>
    </tr>
</table>

<hr>

<h2>Detailed Analysis by Formulation</h2>

<div class="info-box">
    <h3>1. Elementary Osmotic Pump (EOP)</h3>
    <p><strong>PK Profile:</strong></p>
    <ul>
        <li>Flattest release curve (true zero-order after 1-2h lag)</li>
        <li>Lowest Cmax of all options (~8-12 ng/mL)</li>
        <li>Most predictable - independent of GI motility, pH, food</li>
    </ul>
    <p><strong>PK Confidence: 75%</strong></p>
    <ul>
        <li>Established technology (Alza OROS systems)</li>
        <li>Requires precise orifice size - manufacturing variability can affect release</li>
    </ul>
    <p><strong>Patent Confidence: 90%</strong></p>
    <ul>
        <li><strong>Completely different mechanism:</strong> Osmotic pressure through semipermeable membrane vs. HPMC gel diffusion/erosion</li>
        <li>No HPMC in formulation</li>
        <li>Veradermics cannot claim this without new patents</li>
    </ul>
</div>

<div class="info-box">
    <h3>2. Controlled Porosity Osmotic Pump (CPOP)</h3>
    <p><strong>PK Profile:</strong></p>
    <ul>
        <li>Near zero-order after membrane hydration</li>
        <li>Slightly more variable than EOP due to in-situ pore formation</li>
    </ul>
    <p><strong>PK Confidence: 65%</strong></p>
    <ul>
        <li>Pore formation can be inconsistent batch-to-batch</li>
        <li>Less predictable than laser-drilled EOP</li>
        <li>More development work needed</li>
    </ul>
    <p><strong>Patent Confidence: 90%</strong></p>
    <ul>
        <li>Osmotic mechanism, cellulose acetate membrane</li>
        <li>Completely distinct from HPMC matrix</li>
    </ul>
</div>

<div class="success-box">
    <h3>3. Multi-Particulate System (MUPS) - RECOMMENDED</h3>
    <p><strong>PK Profile:</strong></p>
    <ul>
        <li>First-order diffusion through ethylcellulose coating</li>
        <li>Cmax slightly higher than osmotic systems but well within safe range</li>
        <li>Tmax 2-5 hours - good therapeutic window</li>
    </ul>
    <p><strong>PK Confidence: 85% (Highest)</strong></p>
    <ul>
        <li>Most established technology in generic ER market</li>
        <li>Ethylcellulose/Eudragit coatings extremely well-characterized</li>
        <li>Predictable scale-up from lab to commercial</li>
        <li>Multiple pellets = dose-dumping risk distributed</li>
    </ul>
    <p><strong>Patent Confidence: 95% (Highest)</strong></p>
    <ul>
        <li><strong>Different dosage form entirely</strong> (pellets in capsule vs. monolithic tablet)</li>
        <li><strong>Different polymer system</strong> (ethylcellulose coating vs. HPMC matrix)</li>
        <li><strong>Different mechanism</strong> (membrane diffusion vs. gel erosion)</li>
        <li>Veradermics patent specifically claims "tablet" and "HPMC matrix"</li>
    </ul>
</div>

<div class="highlight">
    <h3>4. Lipid Matrix Tablet - 2nd Choice</h3>
    <p><strong>PK Profile:</strong></p>
    <ul>
        <li>Extended release via lipid erosion</li>
        <li>Potentially more variable with food (high-fat meals may accelerate release)</li>
    </ul>
    <p><strong>PK Confidence: 60%</strong></p>
    <ul>
        <li>Food effect is a concern - lipid matrices can be sensitive</li>
        <li>May need fed/fasted bioequivalence studies</li>
        <li>Less predictable than polymer systems</li>
    </ul>
    <p><strong>Patent Confidence: 95%</strong></p>
    <ul>
        <li><strong>Fundamentally different chemistry:</strong> Hydrophobic lipid vs. hydrophilic polymer</li>
        <li>Compritol/Precirol are lipids, not HPMC</li>
        <li>No overlap with Veradermics claims</li>
    </ul>
</div>

<div class="info-box">
    <h3>5. Bi-Layer Push-Pull Osmotic</h3>
    <p><strong>PK Profile:</strong></p>
    <ul>
        <li>Excellent zero-order delivery</li>
        <li>Mechanical pumping = very consistent release</li>
    </ul>
    <p><strong>PK Confidence: 70%</strong></p>
    <ul>
        <li>Complex manufacturing (bi-layer compression, laser drilling)</li>
        <li>Higher cost, more things can go wrong</li>
        <li>But when done right, very reliable</li>
    </ul>
    <p><strong>Patent Confidence: 90%</strong></p>
    <ul>
        <li>Two-compartment system vs. single-layer matrix</li>
        <li>Uses PEO (polyethylene oxide), not HPMC</li>
        <li>Osmotic/mechanical mechanism</li>
    </ul>
</div>

<hr>

<h2>Patent Differentiation Summary</h2>

<p>Veradermics' key claims from <a href="https://patents.google.com/patent/US12268688B2/en">US12268688B2</a>:</p>

<table>
    <tr>
        <th>Veradermics Claims</th>
        <th>Our Formulations</th>
    </tr>
    <tr>
        <td>HPMC K4M, K200M as release-controlling matrix</td>
        <td><strong>No HPMC matrix</strong> - EOP, CPOP, Lipid use none; MUPS uses minimal HPMC E5 as binder only (not release-controlling)</td>
    </tr>
    <tr>
        <td>Hydrophilic gel diffusion/erosion mechanism</td>
        <td><strong>Different mechanisms:</strong> Osmotic pressure, membrane diffusion, or lipid erosion</td>
    </tr>
    <tr>
        <td>Monolithic tablet dosage form</td>
        <td><strong>Different forms:</strong> Capsule with pellets (MUPS), bi-layer tablet (Push-Pull)</td>
    </tr>
    <tr>
        <td>Single-layer matrix system</td>
        <td><strong>Multi-unit or bi-compartment:</strong> Multi-particulate pellets or two-layer osmotic</td>
    </tr>
</table>

<div class="warning-box">
    <p><strong>Critical Note on MUPS:</strong> The HPMC E5 (15mg) in our MUPS formula is used only as a <strong>binder for drug layering</strong> onto pellet cores - it does NOT control release. The release-controlling polymer is <strong>ethylcellulose (Surelease)</strong>, which is fundamentally different from Veradermics' HPMC matrix mechanism.</p>
</div>

<hr>

<h2>Development Recommendation</h2>

<div class="success-box">
    <h3>Recommended Path to Market</h3>
    <table>
        <tr>
            <th>Rank</th>
            <th>Formulation</th>
            <th>Rationale</th>
        </tr>
        <tr style="background-color: #e6f4ea;">
            <td><strong>1st</strong></td>
            <td><strong>MUPS</strong></td>
            <td>Highest confidence on both PK (85%) and patent (95%). Established regulatory pathway. No specialized equipment needed.</td>
        </tr>
        <tr>
            <td><strong>2nd</strong></td>
            <td><strong>Lipid Matrix</strong></td>
            <td>Strong patent differentiation (95%). Simple manufacturing. Food effect needs study.</td>
        </tr>
        <tr>
            <td><strong>3rd</strong></td>
            <td><strong>EOP</strong></td>
            <td>Excellent PK profile. Requires laser drilling equipment investment.</td>
        </tr>
    </table>
</div>

<hr>

<h2>Important Caveat</h2>

<div class="highlight">
    <p>These are <strong>design-around formulations</strong>, not <strong>bioequivalent generics</strong>. We are targeting:</p>
    <ul>
        <li><strong>Similar therapeutic outcome</strong> (hair growth efficacy)</li>
        <li><strong>Safe PK profile</strong> (Cmax below cardiac threshold of ~20-25 ng/mL)</li>
        <li><strong>Different release mechanism</strong> (patent freedom-to-operate)</li>
    </ul>
    <p>We do <strong>NOT</strong> need to match Veradermics' exact PK curve - we just need to stay in the therapeutic window while avoiding their specific patent claims.</p>
</div>

<hr>

<h2>Sources</h2>
<ol>
    <li><a href="https://www.veradermics.com/veradermics-completes-phase2-3-enrollment/">Veradermics Phase 2/3 Enrollment Announcement</a></li>
    <li><a href="https://www.veradermics.com/our-pipeline/about-vdphl01/">VDPHL01 Product Page</a></li>
    <li><a href="https://clinicaltrials.gov/study/NCT06527365">ClinicalTrials.gov NCT06527365</a></li>
    <li><a href="https://patents.google.com/patent/US12268688B2/en">US Patent 12268688B2</a></li>
    <li><a href="https://patents.google.com/patent/WO2024091572A1/en">WIPO Patent WO2024091572A1</a></li>
</ol>

<hr>

<p><em>This document is for competitive intelligence and product development purposes. It does not constitute legal advice. Consult a patent attorney before proceeding with development.</em></p>

<p><em>Document prepared: February 5, 2026</em></p>

</body>
</html>
